How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "9065"
  ["article_id"]=>
  string(4) "9065"
  [1]=>
  string(169) "LEO Pharma Inc. Announces U.S. FDA Approval of Adbry (tralokinumab-ldrm) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years"
  ["article_title"]=>
  string(169) "LEO Pharma Inc. Announces U.S. FDA Approval of Adbry (tralokinumab-ldrm) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years"
  [2]=>
  string(153) "&#nlAdbry is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine"
  ["short_description"]=>
  string(153) "&#nlAdbry is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine"
  [3]=>
  string(256) "&#nlAdbry is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine, one of the key drivers of atopic dermatitis signs and symptoms.1,2,3&#nlThere are an estimated 2.4..."
  ["description"]=>
  string(256) "&#nlAdbry is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine, one of the key drivers of atopic dermatitis signs and symptoms.1,2,3&#nlThere are an estimated 2.4..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(140) "https://www.drugs.com/newdrugs/leo-pharma-inc-announces-u-s-fda-approval-adbry-tralokinumab-ldrm-moderate-severe-atopic-dermatitis-6165.html"
  ["blog_url"]=>
  string(140) "https://www.drugs.com/newdrugs/leo-pharma-inc-announces-u-s-fda-approval-adbry-tralokinumab-ldrm-moderate-severe-atopic-dermatitis-6165.html"
  [15]=>
  string(19) "2023-12-15 09:12:12"
  ["add_date"]=>
  string(19) "2023-12-15 09:12:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

LEO Pharma Inc. Announces U.S. FDA Approval of Adbry (tralokinumab-ldrm) for the Treatment

&#nlAdbry is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting

array(40) {
  [0]=>
  string(4) "9066"
  ["article_id"]=>
  string(4) "9066"
  [1]=>
  string(170) "FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI"
  ["article_title"]=>
  string(170) "FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI"
  [2]=>
  string(150) "RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 --  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the "
  ["short_description"]=>
  string(150) "RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 --  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the "
  [3]=>
  string(249) "RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 --  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Welireg, an oral hypoxia-inducible factor-2..."
  ["description"]=>
  string(249) "RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 --  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Welireg, an oral hypoxia-inducible factor-2..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(138) "https://www.drugs.com/newdrugs/fda-approves-merck-s-welireg-belzutifan-patients-advanced-renal-cell-carcinoma-rcc-following-pd-1-6177.html"
  ["blog_url"]=>
  string(138) "https://www.drugs.com/newdrugs/fda-approves-merck-s-welireg-belzutifan-patients-advanced-renal-cell-carcinoma-rcc-following-pd-1-6177.html"
  [15]=>
  string(19) "2023-12-15 06:12:17"
  ["add_date"]=>
  string(19) "2023-12-15 06:12:17"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Patients With Advanc

RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Can

array(40) {
  [0]=>
  string(4) "9067"
  ["article_id"]=>
  string(4) "9067"
  [1]=>
  string(85) "FDA Approves iDose TR (travoprost intracameral implant) for the Treatment of Glaucoma"
  ["article_title"]=>
  string(85) "FDA Approves iDose TR (travoprost intracameral implant) for the Treatment of Glaucoma"
  [2]=>
  string(150) "ALISO VIEJO, Calif.--(BUSINESS WIRE) December 14, 2023 --  Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical compa"
  ["short_description"]=>
  string(150) "ALISO VIEJO, Calif.--(BUSINESS WIRE) December 14, 2023 --  Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical compa"
  [3]=>
  string(243) "ALISO VIEJO, Calif.--(BUSINESS WIRE) December 14, 2023 --  Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal..."
  ["description"]=>
  string(243) "ALISO VIEJO, Calif.--(BUSINESS WIRE) December 14, 2023 --  Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(103) "https://www.drugs.com/newdrugs/fda-approves-idose-tr-travoprost-intracameral-implant-glaucoma-6160.html"
  ["blog_url"]=>
  string(103) "https://www.drugs.com/newdrugs/fda-approves-idose-tr-travoprost-intracameral-implant-glaucoma-6160.html"
  [15]=>
  string(19) "2023-12-15 04:12:34"
  ["add_date"]=>
  string(19) "2023-12-15 04:12:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves iDose TR (travoprost intracameral implant) for the Treatment of Glaucoma

ALISO VIEJO, Calif.--(BUSINESS WIRE) December 14, 2023 -- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical techn

array(40) {
  [0]=>
  string(4) "9049"
  ["article_id"]=>
  string(4) "9049"
  [1]=>
  string(175) "8th Avenue Pharmacy Issues Voluntary Nationwide Recall of Notoginseng Formula Special Gout Granule Due to the Presence of Hidden Drug Ingredients, Diclofenac and Dexamethasone"
  ["article_title"]=>
  string(175) "8th Avenue Pharmacy Issues Voluntary Nationwide Recall of Notoginseng Formula Special Gout Granule Due to the Presence of Hidden Drug Ingredients, Diclofenac and Dexamethasone"
  [2]=>
  string(150) "Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 14, 2023 -- Brooklyn, NY, 8th Avenue Pharmacy is voluntarily recalli"
  ["short_description"]=>
  string(150) "Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 14, 2023 -- Brooklyn, NY, 8th Avenue Pharmacy is voluntarily recalli"
  [3]=>
  string(249) "Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 14, 2023 -- Brooklyn, NY, 8th Avenue Pharmacy is voluntarily recalling all lots within expiry of Notoginseng Formula Special Gout Granule, distributed by 8th Avenue..."
  ["description"]=>
  string(249) "Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 14, 2023 -- Brooklyn, NY, 8th Avenue Pharmacy is voluntarily recalling all lots within expiry of Notoginseng Formula Special Gout Granule, distributed by 8th Avenue..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(136) "https://www.drugs.com/fda/8th-avenue-pharmacy-issues-voluntary-nationwide-recall-notoginseng-formula-special-gout-granule-due-14641.html"
  ["blog_url"]=>
  string(136) "https://www.drugs.com/fda/8th-avenue-pharmacy-issues-voluntary-nationwide-recall-notoginseng-formula-special-gout-granule-due-14641.html"
  [15]=>
  string(19) "2023-12-14 19:27:00"
  ["add_date"]=>
  string(19) "2023-12-14 19:27:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

8th Avenue Pharmacy Issues Voluntary Nationwide Recall of Notoginseng Formula Special Gout

Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 14, 2023 -- Brooklyn, NY, 8th Avenue P

array(40) {
  [0]=>
  string(4) "9050"
  ["article_id"]=>
  string(4) "9050"
  [1]=>
  string(140) "WS Global Issues Nationwide Recall of Himalayan Pain Relief Tea Due to the Presence of Hidden Drug Ingredients, Diclofenac and Dexamethasone"
  ["article_title"]=>
  string(140) "WS Global Issues Nationwide Recall of Himalayan Pain Relief Tea Due to the Presence of Hidden Drug Ingredients, Diclofenac and Dexamethasone"
  [2]=>
  string(150) "Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 13, 2023 –WS Global, INC Brooklyn, NY is voluntarily recalling"
  ["short_description"]=>
  string(150) "Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 13, 2023 –WS Global, INC Brooklyn, NY is voluntarily recalling"
  [3]=>
  string(250) "Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 13, 2023 –WS Global, INC Brooklyn, NY is voluntarily recalling all lots of Himalayan Pain Relief Tea, tea packets to the consumer level. The products have been..."
  ["description"]=>
  string(250) "Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 13, 2023 –WS Global, INC Brooklyn, NY is voluntarily recalling all lots of Himalayan Pain Relief Tea, tea packets to the consumer level. The products have been..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(128) "https://www.drugs.com/fda/ws-global-issues-nationwide-recall-himalayan-pain-relief-tea-due-presence-hidden-diclofenac-14642.html"
  ["blog_url"]=>
  string(128) "https://www.drugs.com/fda/ws-global-issues-nationwide-recall-himalayan-pain-relief-tea-due-presence-hidden-diclofenac-14642.html"
  [15]=>
  string(19) "2023-12-14 02:40:00"
  ["add_date"]=>
  string(19) "2023-12-14 02:40:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

WS Global Issues Nationwide Recall of Himalayan Pain Relief Tea Due to the Presence of Hid

Audience: Consumer, Patient, Health Professional, Pharmacy, Rheumatology December 13, 2023 –WS Global, INC Brookly

array(40) {
  [0]=>
  string(4) "9297"
  ["article_id"]=>
  string(4) "9297"
  [1]=>
  string(59) "Small Kaizen Generates Big Savings at Toyota Assembly Plant"
  ["article_title"]=>
  string(59) "Small Kaizen Generates Big Savings at Toyota Assembly Plant"
  [2]=>
  string(158) "&#nl        Occasionally a low-cost change comes along that generates massive savings. At Toyota Motor Corp.’s assembly plant in Buffalo, WV, the manuf"
  ["short_description"]=>
  string(158) "&#nl        Occasionally a low-cost change comes along that generates massive savings. At Toyota Motor Corp.’s assembly plant in Buffalo, WV, the manuf"
  [3]=>
  string(437) "&#nl        
Occasionally a low-cost change comes along that generates massive savings. At Toyota Motor Corp.’s assembly plant in Buffalo, WV, the manufacturing team came up with just such an extraordinary innovation.&#nl
&#nl      "
  ["description"]=>
  string(437) "&#nl        
Occasionally a low-cost change comes along that generates massive savings. At Toyota Motor Corp.’s assembly plant in Buffalo, WV, the manufacturing team came up with just such an extraordinary innovation.&#nl
&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "100"
  ["rss_id"]=>
  string(3) "100"
  [14]=>
  string(102) "https://www.assemblymag.com/articles/98201-small-kaizen-generates-big-savings-at-toyota-assembly-plant"
  ["blog_url"]=>
  string(102) "https://www.assemblymag.com/articles/98201-small-kaizen-generates-big-savings-at-toyota-assembly-plant"
  [15]=>
  string(19) "2023-12-13 22:00:00"
  ["add_date"]=>
  string(19) "2023-12-13 22:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Small Kaizen Generates Big Savings at Toyota Assembly Plant

&#nl 

array(40) {
  [0]=>
  string(4) "9197"
  ["article_id"]=>
  string(4) "9197"
  [1]=>
  string(59) "EMA recommends approval of ranibizumab biosimilar Rimmyrah "
  ["article_title"]=>
  string(59) "EMA recommends approval of ranibizumab biosimilar Rimmyrah "
  [2]=>
  string(155) "<p>The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use announced on 9 November 2023 that it had recommended g"
  ["short_description"]=>
  string(155) "<p>The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use announced on 9 November 2023 that it had recommended g"
  [3]=>
  string(295) "<p>The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use announced on 9 November 2023 that it had recommended granting of marketing authorization for&nbsp;Rimmyrah (ranibizumab), a biosimilar that references ophthalmology drug, Lucentis.</p>"
  ["description"]=>
  string(295) "<p>The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use announced on 9 November 2023 that it had recommended granting of marketing authorization for&nbsp;Rimmyrah (ranibizumab), a biosimilar that references ophthalmology drug, Lucentis.</p>"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(102) "http://www.gabionline.net//biosimilars/news/ema-recommends-approval-of-ranibizumab-biosimilar-rimmyrah"
  ["blog_url"]=>
  string(102) "http://www.gabionline.net//biosimilars/news/ema-recommends-approval-of-ranibizumab-biosimilar-rimmyrah"
  [15]=>
  string(19) "2023-12-12 15:29:31"
  ["add_date"]=>
  string(19) "2023-12-12 15:29:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:43"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

EMA recommends approval of ranibizumab biosimilar Rimmyrah

<p>The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use announced on 9 Nove

array(40) {
  [0]=>
  string(4) "9198"
  ["article_id"]=>
  string(4) "9198"
  [1]=>
  string(58) "Genfar: Eurofarma's new generic brand in Latin America"
  ["article_title"]=>
  string(58) "Genfar: Eurofarma's new generic brand in Latin America"
  [2]=>
  string(150) "<p>Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by "
  ["short_description"]=>
  string(150) "<p>Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by "
  [3]=>
  string(231) "<p>Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by the French company Sanofi, with offices in Colombia, Ecuador, and Peru.</p>"
  ["description"]=>
  string(231) "<p>Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by the French company Sanofi, with offices in Colombia, Ecuador, and Peru.</p>"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(92) "http://www.gabionline.net//pharma-news/genfar-eurofarma-s-new-generic-brand-in-latin-america"
  ["blog_url"]=>
  string(92) "http://www.gabionline.net//pharma-news/genfar-eurofarma-s-new-generic-brand-in-latin-america"
  [15]=>
  string(19) "2023-12-12 15:16:53"
  ["add_date"]=>
  string(19) "2023-12-12 15:16:53"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:43"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Genfar: Eurofarma's new generic brand in Latin America

<p>Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a 

array(40) {
  [0]=>
  string(4) "9199"
  ["article_id"]=>
  string(4) "9199"
  [1]=>
  string(56) "COFEPRIS promotes regulatory cooperation in the Americas"
  ["article_title"]=>
  string(56) "COFEPRIS promotes regulatory cooperation in the Americas"
  [2]=>
  string(155) "<p>During the 60th Executive Council of the Pan American Health Organization (PAHO) held in Washington, DC, USA, on&nbsp;25–28 September 2"
  ["short_description"]=>
  string(155) "<p>During the 60th Executive Council of the Pan American Health Organization (PAHO) held in Washington, DC, USA, on&nbsp;25–28 September 2"
  [3]=>
  string(403) "<p>During the 60th Executive Council of the Pan American Health Organization (PAHO) held in Washington, DC, USA, on&nbsp;25–28 September 2023,&nbsp;Alejandro Svarch Pérez, Head of the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), on behalf of the Mexican government, emphasized the need to strengthen healthcare systems based on primary care.</p>"
  ["description"]=>
  string(403) "<p>During the 60th Executive Council of the Pan American Health Organization (PAHO) held in Washington, DC, USA, on&nbsp;25–28 September 2023,&nbsp;Alejandro Svarch Pérez, Head of the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), on behalf of the Mexican government, emphasized the need to strengthen healthcare systems based on primary care.</p>"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(104) "http://www.gabionline.net//policies-legislation/cofepris-promotes-regulatory-cooperation-in-the-americas"
  ["blog_url"]=>
  string(104) "http://www.gabionline.net//policies-legislation/cofepris-promotes-regulatory-cooperation-in-the-americas"
  [15]=>
  string(19) "2023-12-12 15:08:08"
  ["add_date"]=>
  string(19) "2023-12-12 15:08:08"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:43"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

COFEPRIS promotes regulatory cooperation in the Americas

<p>During the 60th Executive Council of the Pan American Health Organization (PAHO) held in Washington, DC, USA, o

array(40) {
  [0]=>
  string(4) "9298"
  ["article_id"]=>
  string(4) "9298"
  [1]=>
  string(43) "Toyota Outlines Future Production Processes"
  ["article_title"]=>
  string(43) "Toyota Outlines Future Production Processes"
  [2]=>
  string(153) "&#nl        As the auto industry evolves to electric vehicles, Toyota has been forced to retool its production strategy using a combination of cutting-ed"
  ["short_description"]=>
  string(153) "&#nl        As the auto industry evolves to electric vehicles, Toyota has been forced to retool its production strategy using a combination of cutting-ed"
  [3]=>
  string(410) "&#nl        
As the auto industry evolves to electric vehicles, Toyota has been forced to retool its production strategy using a combination of cutting-edge technology and old-school lean thinking.&#nl
&#nl      "
  ["description"]=>
  string(410) "&#nl        
As the auto industry evolves to electric vehicles, Toyota has been forced to retool its production strategy using a combination of cutting-edge technology and old-school lean thinking.&#nl
&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "100"
  ["rss_id"]=>
  string(3) "100"
  [14]=>
  string(86) "https://www.assemblymag.com/articles/98199-toyota-outlines-future-production-processes"
  ["blog_url"]=>
  string(86) "https://www.assemblymag.com/articles/98199-toyota-outlines-future-production-processes"
  [15]=>
  string(19) "2023-12-11 22:00:00"
  ["add_date"]=>
  string(19) "2023-12-11 22:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Toyota Outlines Future Production Processes

&#nl 

array(40) {
  [0]=>
  string(4) "9075"
  ["article_id"]=>
  string(4) "9075"
  [1]=>
  string(119) "FDA Accepts for Review Resubmitted NDA for TransCon PTH (palopegteriparatide) in Adult Patients with Hypoparathyroidism"
  ["article_title"]=>
  string(119) "FDA Accepts for Review Resubmitted NDA for TransCon PTH (palopegteriparatide) in Adult Patients with Hypoparathyroidism"
  [2]=>
  string(150) "COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) --Ascendis Pharma, Inc. (Nasdaq: ASND) today announced that the U.S. Food & Drug Administ"
  ["short_description"]=>
  string(150) "COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) --Ascendis Pharma, Inc. (Nasdaq: ASND) today announced that the U.S. Food & Drug Administ"
  [3]=>
  string(252) "COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) --Ascendis Pharma, Inc. (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for..."
  ["description"]=>
  string(252) "COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) --Ascendis Pharma, Inc. (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(50) "https://www.drugs.com/nda/transcon_pth_231211.html"
  ["blog_url"]=>
  string(50) "https://www.drugs.com/nda/transcon_pth_231211.html"
  [15]=>
  string(19) "2023-12-11 11:12:28"
  ["add_date"]=>
  string(19) "2023-12-11 11:12:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Accepts for Review Resubmitted NDA for TransCon PTH (palopegteriparatide) in Adult Pat

COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) --Ascendis Pharma, Inc. (Nasdaq: ASND) today announced that the

array(40) {
  [0]=>
  string(4) "9051"
  ["article_id"]=>
  string(4) "9051"
  [1]=>
  string(124) "InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets"
  ["article_title"]=>
  string(124) "InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy December 09, 2023 -- Cipla Limited today announced that its wholly-owned subsidiary, InvaGen Pharmac"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy December 09, 2023 -- Cipla Limited today announced that its wholly-owned subsidiary, InvaGen Pharmac"
  [3]=>
  string(250) "Audience: Consumer, Health Professional, Pharmacy December 09, 2023 -- Cipla Limited today announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the..."
  ["description"]=>
  string(250) "Audience: Consumer, Health Professional, Pharmacy December 09, 2023 -- Cipla Limited today announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(134) "https://www.drugs.com/fda/invagen-pharmaceuticals-issues-voluntary-nationwide-recall-vigabatrin-oral-solution-usp-500mg-due-14640.html"
  ["blog_url"]=>
  string(134) "https://www.drugs.com/fda/invagen-pharmaceuticals-issues-voluntary-nationwide-recall-vigabatrin-oral-solution-usp-500mg-due-14640.html"
  [15]=>
  string(19) "2023-12-09 18:56:00"
  ["add_date"]=>
  string(19) "2023-12-09 18:56:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution

Audience: Consumer, Health Professional, Pharmacy December 09, 2023 -- Cipla Limited today announced that its wholly-own